Live vaccinations safe and effective among patients taking Dupilumab, reveals Study
The new advancement published in the recent issue of the Annals of Allergy, Asthma & Immunology unveiled promising insights into the safety of vaccinations for patients receiving dupilumab, a monoclonal antibody known for its efficacy in treating a variety of conditions. Dupilumab targets the interleukin (IL)-4 receptor alpha subunit to effectively block the inflammatory effects of IL-4 and IL-13, this makes it a valuable treatment for diseases such as asthma, atopic dermatitis, and eosinophilic esophagitis.
Previously, clinical trials that involved dupilumab have taken a cautious approach by excluding patients from receiving live vaccines. This precaution was reflected in the package insert that advises against administering live vaccines to individuals who undergo treatment with dupilumab. This recommendation was to prevent any potential adverse effects stemming from the immune-modulating properties of the drug. The recent approval of dupilumab use in treating atopic dermatitis in patients as young as six months has raised concerns on the pediatric patients who typically follow a vaccination schedule that includes live vaccines.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.